Publication Name	World Journal of Biological Chemistry
Manuscript ID	18703
Country	Italy

Received	2015-04-27 11:11
Peer-Review Started	2015-04-28 08:25
To Make the First Decision	2015-05-14 16:45
Return for Revision	2015-05-19 09:28
Revised	2015-05-30 21:28
Second Decision	2015-07-09 08:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-07-23 16:51
Articles in Press	2015-07-23 16:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-11 13:27
Publish the Manuscript Online	2015-08-26 11:07

ISSN	1949-8454 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Current medical treatment of estrogen receptor-positive breast cancer
Manuscript Source	Invited Manuscript
All Author List	Franco Lumachi, Davide A Santeufemia and Stefano MM Basso
Funding Agency and Grant Number
Corresponding Author	Franco Lumachi, MD, PsyD, Professor, Department of Surgery, Oncology and Gasteroenterology, University of Padua, School of Medicine, via Giustiniani 2, 35128 Padova, Italy. flumachi@unipd.it
Key Words	Breast cancer; Endocrine therapy; GnRH-agonists; Ovarian function suppression; Tamoxifen; Selective estrogen receptor modulator; Aromatase inhibitors
Core Tip	In women with breast cancer (BC), the two major endocrine therapies (ET) available are directed at blocking estrogen receptors (ERs) on cancer cells (selective estrogen receptor modulators), or against the key enzyme in the biosynthesis of estrogens (aromatase inhibitors). The new knowledge about molecular mechanisms regulating tumor progression, suggested the existence of a strict relationship between ERs, intracellular signaling pathways, and other growth factors receptor, which justify the escape of a portion of patients from the inhibitory effects of ET. To restore endocrine sensitivity of BC cells, molecular-target therapies are giving encouraging results, but further studies are required to confirm their real usefulness.
Publish Date	2015-08-26 11:07
Citation	Lumachi F, Santeufemia DA, Basso SMM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 2015; 6(3): 231-239
URL	http://www.wjgnet.com/1949-8454/full/v6/i3/231.htm
DOI	http://dx.doi.org/10.4331/wjbc.v6.i3.231

Full Article (PDF)	WJBC-6-231.pdf
Full Article (Word)	WJBC-6-231.doc
Manuscript File	1_Manuscript_18703_revised.doc
Answering Reviewers	2_Answering_Reviewers_18703.pdf
Copyright License Agreement	3_BPG_Copyright_Assignment_18703.pdf
Peer-review Report	18703-Peer-review(s).pdf
Scientific Editor Work List	18703-Scientific editor work list.pdf